Vaccibody Price To Sales vs. Cash Per Share
Based on the key profitability measurements obtained from Vaccibody's financial statements, Vaccibody As may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in April. Profitability indicators assess Vaccibody's ability to earn profits and add value for shareholders.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Please note, there is a significant difference between Vaccibody's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaccibody is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaccibody's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For Vaccibody profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vaccibody to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vaccibody As utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vaccibody's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vaccibody As over time as well as its relative position and ranking within its peers.
Vaccibody |
Vaccibody As Cash Per Share vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vaccibody's current stock value. Our valuation model uses many indicators to compare Vaccibody value to that of its competitors to determine the firm's financial worth. Vaccibody As is rated below average in price to sales category among its peers. It is rated below average in cash per share category among its peers fabricating about 2.24 of Cash Per Share per Price To Sales. Comparative valuation analysis is a catch-all model that can be used if you cannot value Vaccibody by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vaccibody's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Vaccibody Cash Per Share vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Vaccibody |
| = | 2.31 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Vaccibody |
| = | 5.17 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Vaccibody Cash Per Share Comparison
Vaccibody is currently under evaluation in cash per share category among its peers.
Vaccibody Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vaccibody, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vaccibody will eventually generate negative long term returns. The profitability progress is the general direction of Vaccibody's change in net profit over the period of time. It can combine multiple indicators of Vaccibody, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Vaccitech Plc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Vaccibody Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vaccibody. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vaccibody position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vaccibody's important profitability drivers and their relationship over time.
Use Vaccibody in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vaccibody position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaccibody will appreciate offsetting losses from the drop in the long position's value.Vaccibody Pair Trading
Vaccibody As Pair Trading Analysis
The ability to find closely correlated positions to Mattel could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mattel when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mattel - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mattel Inc to buy it.
The correlation of Mattel is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mattel moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mattel Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mattel can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vaccibody position
In addition to having Vaccibody in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run IT Thematic Idea Now
IT
Information Technology (IT) companies and IT service providers across different domains. The IT theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize IT Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |